Galamiton, Elsie T.
HRN: 20-07-85 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/18/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/18/2022
07/25/2022
IV
500mg
Q8H
Cholecystolithiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes